Matthew S. McIlwain - 15 Jun 2023 Form 4 Insider Report for Nautilus Biotechnology, Inc. (NAUT)

Role: Director
Signature: /s/ Anna Mowry, as Attorney-in-Fact
Issuer symbol: NAUT
Transactions as of: 15 Jun 2023
Transactions value $: $0
Form type: 4
Filing time: 16 Jun 2023, 20:07:02 UTC
Previous filing: 27 Feb 2023
Next filing: 20 Jun 2023
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NAUT	Stock Option (Right to Buy)	Award	$0	+45K		$0.00	45K	15 Jun 2023	Common Stock	45K	$3.97	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Subject to reporting person's continuous status as a "Service Provider" (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month).

Content

Subject to reporting person's continuous status as a "Service Provider" (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month).